Ena Segota, MD

Ila Tamaskar, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Matt Kalaycio, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Jaroslaw Maciejewski, MD, PhD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Address: Ila Tamaskar, MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, R35, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail tamasai@ccf.org

Ila Tamaskar, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Matt Kalaycio, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Jaroslaw Maciejewski, MD, PhD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Address: Ila Tamaskar, MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, R35, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail tamasai@ccf.org

Ila Tamaskar, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Matt Kalaycio, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Jaroslaw Maciejewski, MD, PhD
Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic

Address: Ila Tamaskar, MD, Department of Hematology and Medical Oncology, Taussig Cancer Center, R35, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail tamasai@ccf.org

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center,
The Cleveland Clinic Foundation

David Adelstein, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Tarek Mekhail, MD, MSc
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Tarek Mekhail, MD, MSc, Taussig Cancer Center, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mekhait@ccf.org

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center,
The Cleveland Clinic Foundation

David Adelstein, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Tarek Mekhail, MD, MSc
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Tarek Mekhail, MD, MSc, Taussig Cancer Center, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mekhait@ccf.org

Ena Segota, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center,
The Cleveland Clinic Foundation

David Adelstein, MD
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Tarek Mekhail, MD, MSc
Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Tarek Mekhail, MD, MSc, Taussig Cancer Center, R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mekhait@ccf.org

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Ena Segota, MD
Taussig Cancer Center, The Cleveland Clinic Foundation

Ronald M. Bukowski, MD
Director of Experimental Therapeutics Program, Taussig Cancer Center, The Cleveland Clinic Foundation

Address: Ronald M. Bukowski, MD, Taussig Cancer Center, R33, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Bukowski has indicated that he has received grant or research support from the Wyeth, Human Genome Sciences, Bristol-Myers Squibb, and Novartis corporations, is a consultant for Novartis and Celgene, and is on the speaker’s bureau of Schering, Cheron, and Celgene.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.